“The Vaccine That Will Cure Chronic Diseases With Lou Reese” — Moonshots EP #21
Episode summary
Diamandis hosts Lou Reese, his self-described best friend and co-founder of Vaxxinity (public company), for a conversation that’s half personal philosophy and half biotech moonshot. The first 35 minutes cover presence, parenting, work-life integration, the SBF/FTX collapse (recorded days after the arrest), Elon Musk commentary, and macro-economic trends. The biotech portion explains Vaxxinity’s thesis: monoclonal antibodies (Humira, Repatha, etc.) are the most expensive drug class globally ($220B+ annual sales), cost $100K+/patient/year, require cold-chain injection every 2 weeks, and are available to less than 1% of the world. Vaxxinity’s approach is to create vaccines that train the patient’s own immune system to produce the needed antibodies, eliminating the bioreactor manufacturing bottleneck. This could reduce costs by orders of magnitude and make chronic-disease treatments accessible globally. Diamandis discloses he’s co-founder and vice chairman of Vaxxinity. Reese also discusses his philosophy of presence, 2-3 big things per day, and not using email.
Key arguments / segments
- [00:01:00] Introduction: Reese as Diamandis’s best friend, Vaxxinity co-founder
- [00:02:00] Work-life integration philosophy, enjoying the journey
- [00:08:00] Being present with family, avoiding digital distractions, no-email policy
- [00:17:00] SBF/FTX arrest commentary: hubris, lemming investment mindset, QuickBooks accounting
- [00:26:00] Elon Musk: Tesla, SpaceX wins, government headwinds, neuralink vs. Blackrock BCI
- [00:35:00] Vaxxinity moonshot: monoclonal antibodies at $220B/year, $100K+/patient, <1% global access
- [00:40:00] Vaxxinity’s vaccine approach: train the body to make its own antibodies vs. manufacturing them in bioreactors
Bias / commercial flags
- Diamandis is co-founder and vice chairman of Vaxxinity — major conflict of interest
- Extended Levels ad read mid-episode (~2 min)
- Episode is effectively promotional for Vaxxinity (VAXX), a public company
RDCO relevance
Low direct relevance. The biotech/vaccine platform is interesting from a technology-disrupts-incumbents angle but has no AI/data signal. The SBF/FTX commentary is a useful case study in scaling-without-controls. Not actionable for RDCO.